CDKN2A and glioma: In addition, a recent large-scale WGS study using a total of 156 recurrent gliomas arising in patients after radiotherapy found small deletion burden and homozygous deletion of CDKN2A as biomarkers of short survival and recurrence after radiotherapy, respectively [49].